In a five-group rat model of accelerated brain senescence — combining D-galactose administration with fractionated whole-body γ-radiation (1.5 Gy/week × 4 weeks; total 6 Gy) — quinoa seed powder (QSP) delivered statistically significant reductions in amyloid-β1-42 and tau protein accumulation, restored telomerase activity, suppressed malondialdehyde, elevated catalase and reduced glutathione, and shifted autophagy flux toward clearance via LC3B upregulation and mTOR downregulation. Molecular docking identified kaempferol as the lead bioactive, binding mTOR at −7.579 kcal/mol and catalase at −7.286 kcal/mol, with short-timescale molecular dynamics lending structural plausibility to those interactions.
The mechanistic breadth here is genuinely notable: simultaneously touching oxidative stress, proteostasis (Aβ42/tau), telomere biology, and mTOR-autophagy signaling places quinoa in the same multi-target conversation as rapamycin and metformin research — though the comparison should be made cautiously. The mTOR-autophagy axis is one of the best-validated longevity pathways in mammals, so LC3B/mTOR modulation by a dietary food is clinically interesting. That said, critical limitations demand sobriety: this is a rodent study only; D-galactose/radiation is a proxy, not authentic aging; n=10 per group is modest; and kaempferol docking affinities, while promising, are computational predictions requiring in-vitro enzymatic confirmation. Human bioavailability of quinoa's kaempferol is largely unstudied. Incremental-to-confirmatory in its animal-model framing, but the multi-pathway mechanistic data make this a useful hypothesis-generator for future human trials.
